UCB SA (OTCMKTS:UCBJF) Receives Consensus Rating of “Buy” from Brokerages

UCB SA (OTCMKTS:UCBJF) has been assigned a consensus rating of “Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation.

Several analysts have commented on UCBJF shares. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research began coverage on shares of UCB in a report on Monday, February 23rd. They issued an “outperform” rating on the stock.

UCB Trading Down 0.0%

Shares of UCBJF stock opened at $289.12 on Friday. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The firm has a 50-day moving average of $297.96 and a 200-day moving average of $295.13. UCB has a one year low of $168.65 and a one year high of $345.39.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.